Last reviewed · How we verify
NCT05448898
The Efficacy of Traditional Chinese Medicine in Olfactory Dysfunction
NA trial testing Traditional Chinese Medicine CU Xiu Tang in Olfactory Disorder in 278 participants. Status unknown.
30 November 2023
Quick facts
| Lead sponsor | Eye & ENT Hospital of Fudan University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 278 |
| Start date | 15 July 2022 |
| Primary completion | 30 November 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Traditional Chinese Medicine CU Xiu Tang — full drug profile →
- Olfactory Training
Conditions studied
- Olfactory Disorder — all drugs for Olfactory Disorder →
Sponsor
Eye & ENT Hospital of Fudan University
Who can join
Adults 18 to 55, any sex, with Olfactory Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Studies have demonstrated that patients with olfactory dysfunction could improve the olfactory function after olfactory training. But the efficacy of Traditional Chinese Medicine is unknown.The purpose of this study is to evaluate its efficacy in olfactory dysfunction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05448898
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Olfactory Disorder
Currently open trials in the same condition.
- NCT05855369 — Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID) · Phase 2, PHASE3 · recruiting
- NCT06456008 — Prospective Registery of Smell/Taste Clinic Ear/Nose/Throat · recruiting
- NCT04869436 — Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis · Phase 4 · recruiting
- NCT04791436 — Oral and Olfactory Complications of Recovered COVID-19 Patients · recruiting
Other Eye & ENT Hospital of Fudan University trials
Trials by the same sponsor.
- NCT07522879 — A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Re · Phase 2 · not yet recruiting
- NCT07563088 — SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma · not yet recruiting
- NCT07575334 — Acupuncture Therapy for Sudden Sensorineural Hearing Loss · NA · recruiting
- NCT07320508 — Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study · Phase 2 · recruiting
- NCT07315802 — New Pattern of Retinal Laser Treatment for PDR · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05448898 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eye & ENT Hospital of Fudan University
- Last refreshed: 11 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05448898.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing